Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 651.80

-0.3%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: A.J. Mullen	3/1/2022 2:15:36 PM
	of 3557

Regeneron's doesn't seem affected by the news that a partner's patent license has been invalidated. Intellia licensed its IP from the University of California, which lost its patent battle against Harvard/MIT, subject to appeal. statnews.com Intellia is down 19%, while REGN is down just 2%. There's good news for both companies as well as bad: finance.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next